BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome is a recently proposed framework emphasizing the interconnected nature of cardiovascular, kidney, and metabolic disorders. These conditions share risk factors with cancer, but the relationship between CKM stage and cancer risk remains unclear. We aimed to investigate a longitudinal association in a large-scale, nationwide population. METHODS: codes C00-C97). Cox proportional hazards models were used to estimate hazard ratios and 95% CIs, adjusting for demographic, clinical, and lifestyle factors. Subgroup and sensitivity analyses were also performed. RESULTS: Over a median follow-up of 3.4 years, higher baseline CKM stages were associated with increased cancer risk. Adjusted hazard ratios (95% CIs) for cancer were 1.03 (0.99-1.08), 1.02 (0.99-1.05), 1.25 (1.21-1.29), and 1.30 (1.25-1.35) for CKM Stages 1-4, respectively, compared with Stage 0. The stage-specific association was consistent across cancer types and in analyses stratified by age and sex, with similar patterns observed across subgroups. Sensitivity analyses using alternative CKM definitions supported the robustness of the findings. CONCLUSIONS: Advancing baseline CKM stage, particularly Stages 3 and 4, was associated with increased cancer risk. These findings extend the clinical relevance of the CKM framework beyond cardiovascular and kidney outcomes, underscoring the need for integrated risk assessment and prevention in multimorbid individuals.
Azegami et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: